Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1996-2-23
|
| pubmed:abstractText |
60 patients undergoing bone marrow or stem cell transplantation were treated with liposomal Amphotericin-B for documented or suspected mycosis. 34 patients had a prior course of conventional Amphotericin-B with the following adverse effects: increasing creatinine above 1.4 mg/dl (n = 17), increasing creatinine below 1.5 mg/dl (n = 9), no response (n = 6), and clinical side-effects (n = 4). Liposomal Amphotericin-B failed in 6/7 patients with culture-proven mycosis who died from infection with Aspergillus (n = 2) and Candida (n = 4), respectively. One patient with Candida lambica sepsis was cured. No patient with clinically or serologically suspected or diagnosed infection died from mycosis. Liposomal Amphotericin-B was well tolerated in 57 patients, even after side-effects of the conventional formulation. Adverse effects occurred in three cases, requiring the withdrawal of the drug in one patient. Due to toxic side-effects of the high-dose therapy and transplant-related complications, it was difficult to evaluate the influence of liposomal Amphotericin-B on laboratory parameters. Eight patients showed a decrease of creatinine levels, which had increased above normal values under preceding therapy with conventional Amphotericin-B. Liposomal Amphotericin-B is well tolerated in patients undergoing high-dose therapy and bone marrow transplantation. The efficacy of liposomal Amphotericin-B needs to be investigated in randomized studies in comparison with conventional Amphotericin-B.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0007-1048
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
91
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
684-90
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:8555076-Adolescent,
pubmed-meshheading:8555076-Adult,
pubmed-meshheading:8555076-Amphotericin B,
pubmed-meshheading:8555076-Antifungal Agents,
pubmed-meshheading:8555076-Aspergillosis,
pubmed-meshheading:8555076-Bone Marrow Transplantation,
pubmed-meshheading:8555076-Child,
pubmed-meshheading:8555076-Child, Preschool,
pubmed-meshheading:8555076-Female,
pubmed-meshheading:8555076-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:8555076-Humans,
pubmed-meshheading:8555076-Infant,
pubmed-meshheading:8555076-Lung Diseases, Fungal,
pubmed-meshheading:8555076-Male,
pubmed-meshheading:8555076-Middle Aged,
pubmed-meshheading:8555076-Mycoses,
pubmed-meshheading:8555076-Neutropenia,
pubmed-meshheading:8555076-Opportunistic Infections,
pubmed-meshheading:8555076-Treatment Outcome
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation.
|
| pubmed:affiliation |
Department of Oncology/Haematology, University Hospital Eppendorf, Hamburg, Germany.
|
| pubmed:publicationType |
Journal Article
|